



Molecular Partners Publishes Invitation to Annual General Meeting 2021

March 26, 2021

Zurich-Schlieren, Switzerland, March 26, 2021. [Molecular Partners AG](#) (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today published the invitation to the Annual General Meeting 2021.

The Annual General Meeting will be held on Wednesday, April 21, 2021, 2.00 pm CET, at the [registered office of](#) Molecular Partners AG, Wagistrasse 14, 8952 Schlieren, Switzerland.

In view of the current pandemic situation and in accordance with the applicable COVID-19 regulations, the Board of Directors of Molecular Partners AG has decided to conduct the Annual General Meeting without the physical presence of shareholders.

The Board of Directors greatly regrets that this decision was without alternative. As a result, shareholders of Molecular Partners AG may exercise their rights at the Annual General Meeting **exclusively via written or electronically submitted instructions to the independent proxy.**

- [Invitation](#) to the Annual General Meeting 2021 with the corresponding agenda items
- [Einladung](#) zur Generalversammlung 2021 mit den zugehörigen Traktandenpunkten

Financial Calendar

| | |
|----------------|---|
| 21 April 2021 | Annual General Meeting |
| 12 May 2021 | Interim Management Statement Q1 2021 |
| 26 August 2021 | Publication of Half-year Results 2021 (unaudited) |

This calendar is always viewable at [this link](#).

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

For more information see www.molecularpartners.com and follow the Company on Twitter at [@MolecularPartners](#).

For further details, please contact:

Investors:

Seth Lewis

seth.lewis@molecularpartners.com

Tel: +1 781 420 2361

Media:

Shai Biran, Ph.D.

shai.biran@molecularpartners.com

Tel: +1 978 254 6286

Thomas Schneckeburger, European IR & Media

thomas.schneckeburger@molecularpartners.com

Tel: +41 79 407 9952

Forward-looking statements

This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company's control. These statements may include, without limitation, any

statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information.